MRK vs PAHC
MRK: Merck & Co. is a leading global biopharmaceutical firm dedicated to delivering life-saving vaccines and innovative therapeutic medicines for major disease areas. PAHC: Phibro Animal Health is a diversified global provider of animal health and nutritional solutions for livestock and companion animals, supplemented by a specialty chemicals business.
Side-by-side fundamentals
| Metric | MRK | PAHC | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $142.38 | $37.40 | |
| Market cap | $351.3B | $1.5B | |
| P/E as of 2026-10-08 | 113.71 | 16.07 | PAHC lower |
| Net margin | +28.1% | +6.6% | MRK higher |
| Gross margin FY2026, SEC XBRL | n/a | +33.8% | |
| Operating margin FY2026, SEC XBRL | n/a | +12.8% | |
| ROE | +34.7% | +25.9% | MRK higher |
| ROA | +13.3% | +6.6% | MRK higher |
| Debt / equity as of 2026-09-03 | 1.07 | 2.03 | MRK lower |
| Revenue growth (YoY) as of 2026-09-03 | +4.6% | +26.0% | PAHC higher |
| Revenue CAGR (3y) SEC XBRL | +3.1% | +15.8% | PAHC higher |
| Dividend yield as of 2026-09-03 | +2.3% | +1.4% | MRK higher |
| Dividend streak (yrs) SEC XBRL | 19 | 12 | MRK higher |
| Beta as of 2026-09-03 | 0.30 | 1.06 | |
| 1-year return as of 2026-10-08 close | +64.8% | +0.8% | MRK higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.